Diagnostic Approach and Treatment of Pancytopenia in B-Cell Lymphoma

Immediate Diagnostic Workup

The European Society for Medical Oncology recommends obtaining bone marrow aspirate and biopsy to evaluate the cause of cytopenia, as this is essential before determining treatment strategy 1, 3
The differential diagnosis includes lymphomatous marrow infiltration causing disease-related cytopenias, which can be evaluated through bone marrow biopsy 1
Obtaining Coombs test and platelet-associated immunoglobulin testing is recommended to evaluate for autoimmune phenomena 3, 4
Checking for active infection is crucial, as patients with absolute neutrophil count <1.0 × 10⁹/L are at high risk and may require infection control before definitive lymphoma therapy 5, 2

The American Society of Hematology recommends initiating corticosteroids as first-line therapy for autoimmune thrombocytopenia or hemolytic anemia 3, 1, 2
If refractory to corticosteroids, consider rituximab or anti-CD20 antibody-based therapy, as recommended by the European Society for Medical Oncology 2
Treatment indication exists when cytopenias are caused by marrow infiltration (hemoglobin <100 g/L or platelets <100 × 10⁹/L), and lymphoma-directed therapy should be initiated 1
Before initiating lymphoma-directed therapy, assess TP53 mutation and del(17p) status by FISH, as these predict poor response to conventional chemotherapy 3, 1
Evaluate IGHV mutation status to guide treatment selection, as recommended by the International Workshop on Chronic Lymphocytic Leukemia 1, 2

For fit patients with B-cell lymphoma and cytopenias, fludarabine plus cyclophosphamide (FC) or rituximab-based chemoimmunotherapy regimens are recommended for chronic lymphocytic leukemia/small lymphocytic lymphoma 3, 1
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) every 21 days is standard for diffuse large B-cell lymphoma, as recommended by the National Comprehensive Cancer Network 6
For patients with del(17p) or TP53 mutations, alemtuzumab monotherapy or BTK inhibitors (ibrutinib) should be considered, as these patients frequently do not respond to conventional chemotherapy 3, 1

Avoid dose reductions of chemotherapy due to hematologic toxicity in patients treated with curative intent, as this compromises outcomes, and instead use prophylactic hematopoietic growth factors for febrile neutropenia 6
Control active infections before initiating purine analog-based therapy, as these agents cause profound and prolonged immunosuppression lasting >12 months 5
Monitor for tumor lysis syndrome in patients with high tumor burden when initiating treatment, as recommended by the European Society for Medical Oncology 6